Needham Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Pliant Therapeutics (NASDAQ:PLRX) and maintained a $38 price target.
April 10, 2024 | 10:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterated a Buy rating on Pliant Therapeutics and maintained a $38 price target.
The reiteration of a Buy rating and maintenance of a $38 price target by a reputable analyst suggests a strong confidence in Pliant Therapeutics' future performance. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100